Press release
Multiple Sclerosis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, and others.
Multiple Sclerosis Pipeline
Key Takeaways from the Multiple Sclerosis Pipeline Report
• DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Multiple Sclerosis treatment.
• The leading companies working in the Multiple Sclerosis Market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Promising Multiple Sclerosis Pipeline Therapies in the various stages of development rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others.
• September 2023: ImStem Biotechnology announced a study of phase 1 clinical trials for IMS001. This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.
• October 2023: Hoffmann-La Roche announced a study of phase 3 clinical trials for Ocrelizumab. This double-blind, study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over at least 96 weeks.
Request a sample and discover the recent advances in Multiple Sclerosis Treatment Drugs @ Multiple Sclerosis Pipeline Report- https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Multiple Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Multiple Sclerosis Overview
Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord).MS occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibers) in the brain and spinal cord. This attack causes inflammation, which destroys nerve cell processes and myelin - altering electrical messages in the brain. MS is unpredictable and affects each patient differently - some individuals may be mildly affected, while others may lose their ability to write, speak or walk.
Find out more about Multiple Sclerosis Therapeutics Assessment @ Multiple Sclerosis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Multiple Sclerosis Emerging Drugs Profile
• Ublituximab: TG Therapeutics
• IMU-838: Immunic
• ATA188: Atara Biotherapeutics
• ANK-700: ANOKION
Multiple Sclerosis Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Multiple sclerosis therapies. The Multiple sclerosis companies which have their Multiple sclerosis drug candidates in the most advanced stage, i.e. preregistration include, TG Therapeutics.
Learn more about the emerging Multiple Sclerosis Pipeline Therapies @ Multiple Sclerosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Multiple Sclerosis Pipeline Report
• Coverage- Global
• Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Multiple Sclerosis Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Multiple Sclerosis Pipeline Therapies- HIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others
Dive deep into rich insights for new drugs for Multiple Sclerosis Treatment, Visit @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Multiple sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple sclerosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Ublituximab: TG Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EHP 101: Emerald Health Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ASLAN 003: ASLAN Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Lucid MS: FSD Pharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple sclerosis Key Companies
21. Multiple sclerosis Key Products
22. Multiple sclerosis- Unmet Needs
23. Multiple sclerosis- Market Drivers and Barriers
24. Multiple sclerosis- Future Perspectives and Conclusion
25. Multiple sclerosis Analyst Views
26. Multiple sclerosis Key Companies
27. Appendix
For further information on the Multiple Sclerosis Pipeline therapeutics, reach out to Multiple Sclerosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Important Published Links
https://logcworld.mn.co/posts/46134506
https://marketingops.mn.co/posts/46134636
https://motorcycle-events.mn.co/posts/46134899
https://intuitive-schooling.mn.co/posts/46135011
https://plenty-of-heathens.mn.co/posts/advancements-and-market-trends-in-langerhans-cell-histiocytosis-treatment
https://shopsanity.mn.co/posts/understanding-the-langerhans-cell-histiocytosis-market-current-landscape-and-future-prospects
https://mccoterie.mn.co/posts/46135751
https://go02100.mn.co/posts/46136119
https://freesaloneducation.mn.co/posts/46136215
https://sokomtaani.mn.co/posts/46136615
https://skillcrush.mn.co/posts/46136691
https://advicehonest.mn.co/posts/46136795
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple Sclerosis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, and others. here
News-ID: 3320676 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
